2019

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after Multiple myeloma
​Leukemia

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
​Clinical Cancer Research | AACR

Autologous graft versus myeloma: it's not a myth
The Journal of Clinical Investigation

Bone marrow biopsy in low-risk MGUS patients reveals a novel MGUS-like Smoldering multiple myeloma risk group
American Journal of Hematology​

​Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces 
tumor growth in multiple myeloma
Blood Advances

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia
Journal of Clinical Oncology

Monoclonal gammopathy of undetermined significance 
Blood

Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies
JNCI Cancer Spectrum

Mitochondrial metabolism promotes adaptation to proteotoxic stress
Nature Chemical Biology

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia
​Clinical Cancer Research | AACR

Immunotherapy for hematological malignancies
Journal of Life Sciences

Reply to F.D. Leonard (Comment)
Journal of Clinical Oncology

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
American Journal of Hematology

Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma
Nanoscale

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Clinical Cancer Research | AACR